Vanguard Capital Management
MGRX icon

Vanguard Capital Management’s Mangoceuticals MGRX Stock Holding History

Vanguard Capital Management’s Portfolio MGRX Stock Details MGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.8K Hold
123,041
– – ﹤0.01% 3939
2026
Q1 		$44.3K Buy
+123,041
New +$58.9K ﹤0.01% 3929

Other funds holding MGRX

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
ACA
Ackerman Capital Advisors Dallas, Texas $497M AUM 16.31% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
AA
ACT Advisors Asheville, North Carolina $301M AUM 23.36% 1-Year Est. Return

Vanguard Capital Management's MGRX Position: Q2 2026 in Review

Vanguard Capital Management held its Mangoceuticals (MGRX) position steady in Q2 2026 at 123,041 shares worth $46.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3939.

Vanguard Capital Management first reported a position in MGRX in Q1 2026 and has held it in 2 quarters since. 19 funds tracked by Wall St. Rank hold MGRX as of Q2 2026.

  • Vanguard Capital Management held 123,041 shares of Mangoceuticals worth $46.8K as of Q2 2026.
  • Vanguard Capital Management left its Mangoceuticals share count unchanged in Q2 2026.
  • Mangoceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3939 holding.
  • Vanguard Capital Management first reported a position in Mangoceuticals in Q1 2026 and has held it in 2 quarters since.
  • 19 funds tracked by Wall St. Rank held Mangoceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.